CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design A prediction model of simple echocardiographic variables to screen for potentially correctable shunts in adult patients with pulmonary arterial hypertension associated with atrial septal defects: a cross-sectional study Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club Difference in basic concept of coronary bifurcation intervention between Korea and Japan. Insight from questionnaire in experts of Korean and Japanese bifurcation clubs Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings Plaque Rupture, compared to Plaque Erosion, is associated with Higher Level of Pan-coronary Inflammation
|<<... 141 142 143 144 145 146 147 ...>>|

Clinical Trial2018 Oct 27. [Epub ahead of print]

JOURNAL：J Am Coll Cardiol. Article Link

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial

M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators. Keywords: Alirocumab; acute coronary syndrome; total events

FuLL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top